I believe there is a skin test being developed which can determine PKC epsilon levels in the body.
Realizing that the FDA and insurance companies love biomarkers, I can envision a time when this biomarker testing for PKC-e is used to determine the sequencing of how frequently a maintenance dose of 20ug of Bryostatin is given to patients.